On target. A new generation of drugs offers customized cures.
Fischman
Josh
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D010597:Pharmacogenetics; D011799:Quinazolines / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D000068878:Trastuzumab; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011799:Quinazolines; D017978:Receptors, Growth Factor; D000068878:Trastuzumab; D000077156:Gefitinib